Xcout Intel
Enlaza Therapeutics, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Enlaza Therapeutics, Inc. among biotechnology companies — ranked by similarity to what Enlaza Therapeutics, Inc. actually does, not by market-cap band.
Subscribe to see Enlaza Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Enlaza Therapeutics, Inc.
Enlaza Therapeutics, Inc. is a biotechnology enterprise headquartered in California, United States. The company designs and develops next-generation covalent biologic therapeutics targeting serious diseases. It utilizes specialized proprietary discovery platforms to advance precision medicine applications.
Enlaza Therapeutics, Inc. at a glance
Enlaza Therapeutics, Inc. is a biotechnology company headquartered in United States. It has raised at least $150.6M across the 6 funding rounds on record, 4 of them with a disclosed amount. Its most recent funding round raised $15M in August 2025. Xcout tracks 18 named people at Enlaza Therapeutics, Inc., including Sergio Duron (Chief Executive Officer).
Enlaza Therapeutics, Inc. leadership
- Sergio DuronChief Executive Officer
- Analeah Heidt, Ph.D.Chief Scientific Officer
- Sergio Duron, Ph.D.Co-Founder and Chief Executive Officer
- Sanford (Sandy) Madigan, Ph.D.Co-Founder, President and Chief Business Officer
- Joseph (Joe) Woolery, Pharm.D., BCOPSenior Vice President, Head of Clinical Development
- Kara Calhoun, Ph.D.Senior Vice President, Head of CMC and Technical Operations
12 more named people on record for Enlaza Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Enlaza Therapeutics, Inc. funding rounds
At least $150.6M raised across the 6 rounds on record (4 with a disclosed amount). Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $15M | — | |
| Series A | $100M | 2 named | |
| SEC Form D filing | $311,977 | — | |
| SEC Form D filing | Undisclosed | — | |
| SEC Form D filing | Undisclosed | — | |
| SEC Form D filing | $35.3M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Enlaza Therapeutics, Inc. competitors
Ranked by semantic similarity — how close each company is to Enlaza Therapeutics, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotech
Encoded Therapeutics is a biotechnology company headquartered in South San Francisco, California, dedicated to developing next-generation genetic medicines designed to address the root causes of genetic diseases.
Similar biotechnology company
Tyra Biosciences is a biotechnology company headquartered in Carlsbad, California, that develops next-generation precision medicines.
Similar biotechnology company
GeneTether, Inc., also known as Rize Oncology, is a biotechnology company headquartered in San Lorenzo, California, focused on developing proprietary gene-editing technologies and targeted oncology therapeutics.
Life Science
Synthorx, Inc., founded in 2014, is a biotechnology company headquartered in La Jolla, California, that engineered expanded genetic alphabet technologies to discover and develop novel protein therapeutics.
Similar biotechnology company
NextPoint Therapeutics is a private biopharmaceutical and technology company based in Cambridge, Massachusetts, focused on expanding novel therapeutic possibilities.
Biotech
Valerio Therapeutics is a biotechnology company that develops precision-guided therapeutics for complex and underserved diseases. It utilizes a proprietary V-Body conjugate platform, based on synthetic single-domain antibody libraries, to enable targeted drug delivery and deep tissue penetration.
Biotech
Azalea Therapeutics is a biotechnology company headquartered in Berkeley, California. The company focuses on precision genome engineering directly inside the body with an initial emphasis on developing in vivo cancer immunotherapies.
Biotech
Hummingbird Bioscience is a precision biotherapeutics company located in Singapore. It focuses on discovering and developing engineered precision biotherapeutics to define the future of precision medicine.
Similar biotechnology company
HAYA Therapeutics is a precision medicines company developing RNA-guided therapeutics to target regulatory genomic dark matter for serious diseases. The company maintains dual roots with headquarters in Lausanne, Switzerland and a U.S. location in San Diego, California. It operates as a privately held biotech innovator.
Similar biotechnology company
Neuron23 is a biotechnology company founded in 2018 that focuses on developing precision therapeutics for genetic diseases. Headquartered in South San Francisco, California, the company relies on a team of scientific experts and entrepreneurs.
Life Sciences
OncXerna Therapeutics is a clinical-stage precision-oncology biotechnology company that develops RNA-based biomarkers and targeted cancer therapies. Its work is intended to help identify cancer patients most likely to benefit from particular treatments and support oncologists and pharmaceutical partners in treatment selection.
Life Sciences
Iris Medicine is an early-stage life sciences and biotechnology company pioneering allele-selective RNA therapies. Headquartered in California, the company develops novel treatments utilizing its proprietary sbRNA technology platform.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Enlaza Therapeutics, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Enlaza Therapeutics, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →